PPT Slide
- Initiated two Phase II “proof-of-concept” trials with alfimeprase
- Successfully completed interim analysis for Phase II PAO trial
- Successfully monetizing a portion of our non-core assets
- Sequenom license agreement provides up front revenue, potential royalties and patent prosecution savings
- Filed a shelf to offer up to $50MM worth of securities
- Secured sell-side analyst coverage
- Identified four pre-clinical candidates from our antibody target program